Skip to content
Prescott Bio Canada

Tirzepatide: Research Summary

Published: 2026-08-03 · Last updated: 2026-08-03

Mechanism

Tirzepatide is a 39-amino-acid synthetic peptide with dual agonist activity at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The GLP-1 arm drives glucose-dependent insulin secretion, delayed gastric emptying, and central satiety signaling; the GIP arm potentiates insulin secretion and appears to modulate adipocyte function and central appetite pathways in ways that GLP-1 alone does not. A C20 fatty- acid moiety supports albumin binding and a half-life of roughly five days, enabling once-weekly subcutaneous dosing.

Published trials

The SURPASS program (five head-to-head Phase 3 trials in type 2 diabetes) established tirzepatide's glucose-lowering profile: mean HbA1c reductions of roughly 2.0–2.4 percentage points at the highest dose across 40–52 weeks, with weight loss as a secondary endpoint. SURPASS-2 compared tirzepatide directly against semaglutide 1.0 mg weekly and reported superior HbA1c and weight outcomes.

The SURMOUNT program extended into obesity indications. SURMOUNT-1 (participants with obesity or overweight and at least one weight-related comorbidity, without diabetes) reported placebo-subtracted weight loss on the order of 17–21% at 72 weeks depending on dose. SURMOUNT-2 reported the outcome in participants with type 2 diabetes. SURMOUNT-3 evaluated tirzepatide as continuation therapy after intensive lifestyle intervention. A dedicated MASH (metabolic dysfunction-associated steatohepatitis) trial, SYNERGY-NASH, reported histological improvement rates at the higher doses.

Safety profile

The dominant adverse events across the SURPASS and SURMOUNT programs were gastrointestinal — nausea, diarrhea, vomiting, and constipation — concentrated in the dose-escalation window and typically mild-to-moderate. Discontinuation for adverse events ran in the low single digits in most Phase 3 arms. Boxed-warning-adjacent literature discusses medullary thyroid carcinoma (based on rodent findings), pancreatitis, gallbladder disease, and acute kidney injury from severe dehydration. Diabetic retinopathy surveillance was included in the diabetes trials.

How it compares in its class

Tirzepatide is the reference dual-incretin therapy. Head-to-head against semaglutide (SURPASS-2), tirzepatide reduced HbA1c and body weight to a greater extent. Head-to-head against retatrutide, no direct trial has been reported; retatrutide's Phase 2 weight-loss magnitude exceeded tirzepatide's Phase 3 SURMOUNT-1 figures numerically, but Phase 3 confirmation is pending. Within its own class, tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is the pending long-term durability question.

References

  • PMID: 34293246 — Frías JP et al., SURPASS-2: "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." NEJM 2021.
  • PMID: 35658024 — Jastreboff AM et al., SURMOUNT-1: "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM 2022;387:205-216.
  • PMID: 34170647 — Rosenstock J et al., SURPASS-1 tirzepatide monotherapy in type 2 diabetes. Lancet 2021.
  • DOI: 10.1056/NEJMoa2206038 — SURMOUNT-1 (Jastreboff 2022).

Buy Tirzepatide in Canada: Prescott Bio Canada carries Tirzepatide vials — HPLC + mass-spec tested, ships from Richmond BC in 2-4 business days.